

2. (Amended) [Use according to claim] The method of Claim 1 or 20, wherein [the influence is an activation of] said modulating is an activation of blood vessel formation.

3. (Amended) [Use of a tissue factor or a fragment thereof for influencing the] A method for enhancing wound healing in a subject in need, comprising [by induction of a local expression of a tissue factor nucleic acid or by local application of] locally administering a functional tissue factor protein in a therapeutically effective amount to said subject in need.

4. (Amended) [Use according to claim] The method of Claim 3 or 21, wherein the said subject in need is afflicted with [wound healing in the case of] diabetes mellitus, vasculitis, arterial conclusive disease, chronic venous and infected ulcer, innervation impairment, decubital gangrene [and] or weak sutures [in the case of operations is concerned] after a surgery.

5. (Amended) [Use according to claim 1 or] The method of Claim [1 or] 2, wherein [the blood vessel formation in the case of] said subject in need is afflicted with arteriosclerosis, Crohn's disease [and], ulcerative colitis, diabetic retinopathy [and], or deep venous thrombosis of the legs/ulcus cruris [is concerned].

6. (Amended) [Use according to claim 1 or] The method of Claim 2, wherein the blood vessel formation [for replacing] is activated for the replacement of impaired blood vessels [is concerned].

Sub B<sup>1</sup>

7. (Amended) [Use according to any one of claims 1 to 6] The method of Claim  
2, wherein the tissue factor or a fragment thereof is present as expressible nucleic acid.

8. (Amended) [Use according to claim] The method of Claim 7, wherein [the  
expression of the] said nucleic acid is [transient] expressed transiently.

9. (Amended) [Use according to claim] The method of Claim 7 [or 8], wherein  
[the] said nucleic acid is a DNA.

10. (Amended) [Use according to any one of claims] The method of Claim 7 [to  
9], wherein [the] said nucleic acid is controlled by a constitutive or an inducible promoter.

11. (Amended) [Use according to any one of claims] The method of Claim 7 [to  
10], wherein the nucleic acid is present in a Sindbis virus replicon vector.

12. (Amended) [Use according to any one of claims] The method of Claim 7 [to  
10], wherein the nucleic acid is controlled by a CMV or SV40 promoter.

13. (Amended) [Use according to any one of claims] The method of Claim 1 [to  
12], 3, 20, or 21, wherein the tissue factor is present in a liposome or on a carrier, particularly  
gold particle.

005280722460  
091237121082500

14. (Amended) [Use according to any one of claims 1] ~~The method of Claim 13,~~  
wherein the tissue factor is ~~present~~ in combination with further factors promoting the  
formation of blood vessels.

15. (Amended) [Use according to claim] The method of Claim 14, wherein [the]  
said further factors are present as expressible nucleic acids or functional proteins.

16. (Amended) [Use according to claim 14 or] The method of Claim 15, wherein  
[one of the factors] at least one further factor is present and said further factor is VEGF.

17. (Amended) [Use according to any one of claims] ~~The method of Claim 1~~ [to  
16], 3, 20, or 21, wherein the tissue factor is present in a pharmaceutical composition.

Please add the following new Claims 18-21:

18. (New) A pharmaceutical composition for ~~modulation of blood vessel~~  
formation, comprising tissue factor or a fragment thereof and a pharmaceutically acceptable  
carrier.

19. (New) A pharmaceutical composition for activation of blood vessel  
formation, comprising tissue factor or a fragment thereof and a pharmaceutically acceptable  
carrier.